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Abstract: Angioid streaks are visible irregular crack-like dehiscences in Bruch’s membrane 
that are associated with atrophic degeneration of the overlying retinal pigmented epithelium. 
Angioid streaks may be associated with pseudoxanthoma elasticum, Paget’s disease, sickle-cell 
anemia, acromegaly, Ehlers–Danlos syndrome, and diabetes mellitus, but also appear in patients 
without any systemic disease. Patients with angioid streaks are generally asymptomatic, unless 
the lesions extend towards the foveola or develop complications such as traumatic Bruch’s 
membrane rupture or macular choroidal neovascularization (CNV). The visual prognosis 
in patients with CNV secondary to angioid streaks if untreated, is poor and most treatment 
modalities, until recently, have failed to limit the devastating impact of CNV in central vision. 
However, it is likely that treatment with antivascular endothelial growth factor, especially in 
treatment-naive eyes to yield favorable results in the future and this has to be investigated in 
future studies.
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Introduction
Angioid streaks were initially reported in 1889 by Doyne.1 They were described as 
“irregular radial lines spreading from the optic nerve head to the retinal periphery” in a 
patient who had retinal hemorrhages secondary to trauma. Knapp2 ﬁ  rst coined the term 
“angioid streaks” in 1892 because their appearance suggested a vascular origin. Not 
until 1917 did Koﬂ  er3 correctly determine that angioid streaks represented changes at 
the level of Bruch’s membrane. Clinical examination with subsequent histopathological 
ﬁ  ndings by Bock4 in 1938 in two patients with pseudoxanthoma elasticum conﬁ  rmed 
that the underlying abnormality was not vascular in nature but rather a structural 
alteration in Bruch’s membrane. A few years later similar histopathological results 
were found in patients suffering pseudoxanthoma elasticum, Paget’s disease, but also 
from systemic diseases.5 Despite the fact that many systemic diseases like acromegaly, 
Ehlers–Danlos syndrome and diabetes mellitus, have been associated with angioid 
streaks, the most common diseases related to angioid streaks are pseudoxanthoma 
elasticum,6 Paget’s disease7,8 of bone and sickle-cell9 anemia.
Histopathological ﬁ  ndings
Angioid streaks represent visible irregular crack-like dehiscences in Bruch’s membrane 
that are associated with atrophic degeneration of the overlying retinal pigmented 
epithelium (RPE). Histopathology in patients with angioid streaks that suffered from 
pseudoxanthoma elasticum demonstrated calcium deposition in Bruch’s membrane 
which has several well demarcated breaks.10,11 In pseudoxanthoma elasticum, the 
primary lesion is the degeneration of elastic ﬁ  bers of the connective tissue of the 
organism, while the calcium deposition represents a secondary disorder of unknown 
origin.11 In angioid streaks the elastic lamina that occupies the midsegment of Bruch’s 
membrane is affected, resulting in disintegration and frying of the elastic ﬁ  bers. Therapeutics and Clinical Risk Management 2009:5 82
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Electron microscopy (EM) studies showed the presence of 
abundant granulomatous material in this lamina, a fact that 
supports the theory of pathologic elastic ﬁ  bers’ production.
In Paget’s disease the bone deformities lead to calcium 
binding by the elastic ﬁ  bers.12
For several years the appearance of angioid streaks 
in sickle-cell hemoglobinopathies was attributed to high 
level of serum iron.5,13,14 However, other types of anemias 
with increased iron levels in blood are not associated 
with angioid streaks. In addition, histochemical and EM 
studies, which took place in the eyes of patients with 
homozygotic sickle-cell anemia demonstrated severe 
tissue calcification;15 this fact favors the hypothesis that 
angioid streaks in patients with sickle-cell hemoglobin-
pathies are correlated to calcium deposition at Bruch’s 
membrane.
Other histopathological ﬁ  ndings include the break or 
absence of choriocapillaris beneath angioid streaks and 
thinning or decoloration of RPE;16 these changes are identi-
cal in angioid streaks despite different underlying systemic 
diseases.
Ocular manifestations
Angioid streaks are mainly asymptomatic. The appearance 
of symptoms occurs when the angioid streaks involve the 
foveola or in case of choroidal neovascularization (CNV) 
in the macular region (Figures 1, 2).
Angioid streaks have a typical appearance as narrow, 
jagged lines deep to the retina, almost always bilater-
ally. They radiate out in a cruciate pattern from an 
area of peripapillary pigment alterations. They may 
circumferentially ring the peripapillary area as well 
(Figure 1; Figure 2). Angioid streaks are evident in fundos-
copy a few millimetres from the optic disc and rarely occur 
in the periphery of the posterior pole. Clinical diagnosis is 
usually straightforward. Angioid streaks have a thickness of 
50–500 μm and are visible in fundoscopy under the retinal 
vessels.11,15,17,18
The color of angioid streaks depends on the background 
coloration of the fundus and the degree of the atrophy of the 
overlying RPE. Thus, angioid streaks are red in light-colored 
individuals, while in patients who have darker background 
pigmentation, they are usually medium to dark brown. 
Angioid streaks become darker as time passes by and at 
the same time discoloration of RPE occurs. Sometimes 
angioid streaks are extremely dark and have several bonds 
between them giving the appearance of a ‘spider’s web’ in 
the retina. In other occasions a ﬁ  brous connective tissue 
develops around angioid streaks which appear obscure and 
light-colored.11,17,18
In cases where angioid streaks are conﬁ  ned to macula 
and especially if the foveolar avascular zone is affected, 
patients develop metamorphopsia and reduced visual acuity. 
In contrary, if the fovea is unaffected, patients remain 
Figure 1 Red free fundus photo showing typical angioid streaks. Figure 2 Red free fundus photo showing an angioid streak crossing the macula.Therapeutics and Clinical Risk Management 2009:5 83
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asymptomatic and angioid streaks are an accidental ﬁ  nding 
during a routine ophthalmological investigation.
Fluorescein angiography, 
indocyanine green angiography
The photographs taken with the filters of fluorescein 
angiography before the intravenous administration of the 
contrast material (ﬂ  uorescein dye) provide the physician with 
important information because angioid streaks frequently 
present the phenomenon of auto-illumination. Also, optic 
disc drusen which are often associated with angioid streaks 
show auto-illumination in fruoroangiography.11,19
Typically, angioid streaks have a ‘window defect’ in 
ﬂ  uorescein angiography due to atrophy of RPE adjacent to 
them. Leakage of ﬂ  uorescein is evident when CNV is present. 
The diagnosis of angioid streaks is usually made on the basis 
of fundoscopy, but intravenous ﬂ  uorescein angiography 
can help to delineate the presence of the disease when the 
ophthalmoscopic appearance is subtle (Figure 3).20
Indocyanine Green (ICG) angiography is a useful 
diagnostic tool for angioid streaks only in the rare case that 
fundoscopy and ﬂ  uorescein angiography can not conﬁ  rm 
the diagnosis. Such occasions involve the severe lesions of 
RPE which cause hyperﬂ  uorescent lines that are obscure 
or the development of macular CNV; in these cases ICG 
angiography demonstrates the neovascular membrane more 
clearly than ﬂ  uorescein angiography. ICG angiography 
shows hyperﬂ  uorescent lines with ‘pinpoints’ over their 
whole length that are larger and more numerous than those on 
ﬂ  uorescein angiography or red-free photography (Figure 4). 
On the contrary, recently developed angioid streaks become 
evident only at the late stage of the examination and have 
the appearance of hypoﬂ  uorescent linear distortions around 
optic nerve head or posterior pole.11,18
Clinical course, complications
Patients with angioid streaks are generally asymptomatic, 
unless the lesions extend towards the foveola or develop 
complications such as traumatic Bruch’s membrane rupture 
or macular CNV (Figures 5, 6).
The increase in length and width of angioid streaks is 
considered as an expected feature of the disease, but there are 
no clinical studies determining the rate of their propagation 
in correlation with time. Increase in length results in lower 
visual acuity if the angioid streaks spread to the macular 
region and particularly in the foveolar avascular zone.
Patients with angioid streaks may develop breaks of the 
Bruch’s membrane even after relatively mild head injuries 
(traumatic dehiscences in Bruch’s membrane), since their 
Bruch’s membrane is brittle.11 A retrospective study on 
patients with angioid streaks mentioned that 15% of those 
who suffered a head injury developed signiﬁ  cant visual 
impairment.21 Traumatic breaks of Bruch’s membrane are 
frequently followed by subretinal hemorrhages which can 
be easily misinterpreted as CNV. These hemorrhages appear 
usually next to the angioid streaks and sometimes disseminate 
into the macula.21,22
Choroidal neovascularization
The commonest and most serious complication of angioid 
streaks is CNV in the macular region. Such a complication 
deteriorates dramatically the prognosis of angioid streaks 
because it is one of the most difﬁ  cult clinical entities an 
Table 1 Systemic conditions associated with angioid streaks
•  Hemochromatosis
•  Acromegaly
•  Diabetes mellitus
•  Sickle-cell hemoglobinopathies
•  Pseudoxanthoma elasticum
•  Acquired hemolytic anaemia
•  Hereditary spherocytosis
•  Myopia
•  Neuroﬁ  bromatosis
•  Paget’s disease
•  Ehlers–Danlos syndrome
•  Sturge–Weber syndrome
•  Hyperphosphatemia
Figure 3 “Window defect” in ﬂ  uorescein angiography due to atrophy of RPE adjacent 
to angioid streaks.Therapeutics and Clinical Risk Management 2009:5 84
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ophthalmologist can encounter. Patients with angioid streaks 
who develop CNV (Figure 6) are symptomatic and their main 
symptoms are metamorphopsias and reduction of vision.
Fluorescein angiography conﬁ  rms the presence of classic 
CNV in most cases and helps deﬁ  ne the margins of the 
neovascular membrane, which is typically above or right 
next to the angioid streaks (Figures 7, 8). In some occasions 
it is difﬁ  cult to determine the borders of the neovascular 
membrane in fluorescein angiography due to adjacent 
hemorrhages or RPE lesions. In these cases ICG angiography 
is an invaluable diagnostic tool.
The incidence of CNV in patients with angioid 
streaks varies between 72%–86% in numerous studies. 
Commonly, neovascularization involves both eyes, but does 
not occur simultaneously; there is an interval of roughly 
18 months.2,6,11,21,23
The risk of developing CNV increases with age.24 Other 
risk factors comprise the width, length and location of the 
angioid streaks. The wider and longer are the angioid streaks 
the higher the risk for CNV and especially if the lesions are 
located in a distance less than one optic disc diameter from 
the foveola.25,26
Angioid streaks associated with pseudoxanthoma 
elasticum have a relatively high probability of developing 
macular CNV;24 the opposite happens in patients suffering 
sickle-cell anemia.27,28
The standard outcome is poor if CNV in the macular 
region remains untreated because it leads to further exten-
sive formation of subfoveal scarring of CNV causing severe 
deterioration of visual acuity.20 More than 50% of such 
patients eventually become legally blind since their visual 
acuity is less than 1/20.29
Treatment
Laser photocoagulation
The incidence of CNV in patients with angioid streaks 
varies between 72%–86% in different studies. Normally, 
neovascularization involves both eyes, but does not occur 
simultaneously.
The prophylactic therapy of angioid streaks with laser 
beams in order to avoid the development of CNV has been 
used before,30 but it is no longer recommended and many 
researchers strongly believe that this kind of intervention 
can actually induce CNV.31
Photocoagulation with thermal laser was regarded as the 
only possible therapeutic modality for macular CNV and 
consequently was introduced in angioid streaks. Clarkson and 
Figure 4 Indocyanine Green angiography of angioid streaks please note the 
hyperﬂ  uorescent lines with ‘pinpoints’.
Figure 5 Macular hemorrhage complicating an eye with angioid streaks; note 
the “peu d’orange” appearance of the fundus temporal to the macula.
Figure 6 Color fundus photograph in an eye with angioid streaks and choroidal 
neovascularization.Therapeutics and Clinical Risk Management 2009:5 85
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colleagues12 presented a case series report of six patients with 
angioid streaks and CNV of the macular region, who were 
treated with a thermal laser directly targeting the neovascular 
membrane. Their results were devastating and all patients 
developed further expansion of the neovascularization 
causing loss of central vision. At the same time, other small 
case series reports stated that laser photocoagulation had 
some encouraging results in neovascularization outside the 
foveolar region.32–34
In 1988, Gelisken and colleagues35 presented the results of 
a study involving 30 eyes with CNV due to angioid streaks. 
All patients were treated with green argon or krypton laser 
and the follow-up was two months to 16 years. The authors 
concluded that the eyes which had extrafoveolar neovascular 
membranes beneﬁ  ted from the application of thermal laser 
since they retained a useful vision compared to the eyes that 
remained untreated. Additionally, they stressed that in cases 
of subfoveal CNV, no treatment should be applied. Finally, 
they suggested that no statistically signiﬁ  cant difference 
was observed in using argon and krypton laser, but they 
preferred the latter.
During the last 20 years, several clinicians drew the same 
conclusion from these results and thus the dominant con-
temporary theory is that the efﬁ  cacy of photocoagulation for 
macular CNV in angioid streaks is of limited application due 
to the high percentage of neovascular membrane relapse.36
Transpupillary thermotherapy
Recently, ophthalmologists’ interest has switched towards laser 
treatment with reduced use of energy and such an application 
is the diode laser using beams of 810 nm length. Such a laser 
beam has better penetration through the transparent media of 
the eye, better action and well-controlled thermal effect caus-
ing less absorption by the RPE and deeper penetration in the 
choriocapillaris.37,38
Transpupillary thermotherapy uses a diode laser at a 
lower threshold that does not cause thermal burn and has been 
applied for the treatment of macular CNV of any origin. Aras 
and colleagues37 tried this method in patients with subfoveal 
neovascular membranes in angioid streaks and concluded that 
it does not seem to affect the course of the disease and at the 
same time they observed a spreading out of the borders and 
the leakage of the membrane.
Macular translocation surgery
This surgical technique was introduced by Machemer and 
Steinhorst39 in 1993. Macular translocation involves moving 
the neurosensitive retina (macula and varying amounts of 
adjacent retina) to a new location, away from the ingrowth of 
the new vessels. This may be accomplished by limited trans-
location, in which a limited retinal detachment is made and 
the scleral wall is shortened by imbrication or out-pouching, 
or there may be a 360-degree retinotomy, with a rotation of 
the entire retina. This operation is followed by a strabismus 
surgery. Since the ﬁ  rst operation was performed there are 
several modiﬁ  cations by many vitreoretinal surgeons with 
encouraging results.40–43 However, we should stress that it is 
a complex, difﬁ  cult, long-lasting operation which has serious 
complications (retinal detachment, proliferative vitreoreti-
nopathy, endophthalmitis, etc.) threatening the central and 
peripheral vision of the patients.
Macular translocation surgery was used in macular CNV 
in angioid streaks. Roth and colleagues44 described a case 
where they performed a successful lower macular translo-
cation followed by laser photocoagulation in the region of 
choroidal neovasular membrane in a patient with angioid 
streaks. The end result was encouraging and other surgeons 
had similarly good results.45,46 It should be mentioned that 
these encouraging results can not be fully evaluated since 
the number of patients and the studies involved are of a very 
small number.
Photodynamic therapy
Large randomized clinical trials were performed to evaluate 
the efﬁ  cacy of photodynamic therapy (PDT) with verteporﬁ  n 
for CNV secondary to age-related macular degeneration 
(AMD) and pathologic myopia.47–49 Since the results of these 
studies were promising, clinician tried to use PDT in other 
pathological entities causing CNV.
Figure 7 Fluorescein angiography of left eye with angioid streaks complicated by 
choroidal neovascularization.Therapeutics and Clinical Risk Management 2009:5 86
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In 2000, the Archives of Ophthalmology published the 
ﬁ  rst results of the application of PDT for CNV not caused 
by macular degeneration. In this study group there was one 
patient with angioid streaks.50 He was a 55-year-old man 
who was treated only once with PDT and had a 12-month 
follow up. During the follow up time there was no further 
deterioration of his visual acuity, but at the same time the 
leakage of ﬂ  uorescein dye from the neovascular membrane 
remained unaffected.
Two years later, Karacorlu and colleagues51 from the 
‘Istanbul Retina Institute’ in Turkey published their results 
from eight patients with angioid streaks who had PDT. None 
of the patients developed reduction of the visual acuity and 
the average improvement of visual acuity was 1.37 lines on 
the Snellen chart. Three patients had ﬂ  uorescein leak from the 
neovascular membrane during their last visit. Based on these 
results the authors of the article concluded that PDT plays an 
important role in the management of CNV in angioid streaks, 
but they stressed that more studies with larger number of 
patients and longer follow up should be done in order to 
evaluate accurately the efﬁ  ciency of PDT in the treatment 
of macular CNV in angioid streaks.
A year later, Shaikh and colleagues52 presented their 
results in the same journal. Their study encompassed 
11 eyes from nine patients with angioid streaks who had 
PDT for CNV in the macular region. Nine eyes developed a 
disciform scar in the place of CNV at the end of follow-up 
(5–28 months). None of them showed improvement in visual 
acuity and the vast majority of the patients had deteriora-
tion of the vision. The authors point out that one patient 
with bilateral parafoveal CNV had severe visual worsening 
on the eye that was treated according to the PDT protocol 
(repeated every 12 weeks), while the other eye which had 
PDT with early re-treatments (every six weeks) retained its 
visual acuity. As a result, they concluded that PDT does not 
seem to affect the natural course of CNV in angioid streaks 
unless the repetition of treatment was applied in shorter 
intervals. Nonetheless, this publication had the same limita-
tions (small number of patients, short follows up) with the 
previous one.
Similar results were presented during the same year by 
Mennel and colleagues53 who treated with PDT two patients 
with CNV due to angioid streaks: the leakage from the 
neovascular membrane was greater after the PDT.
In 2004, Menchini and colleagues54 published the 
results of a retrospective multicenter clinical trial from 
Italy, which involved 40 patients with angioid streaks who 
developed CNV in the macula and were treated with PDT. 
Visual acuity reduced in 32% of patients with subretinal and 
50% of patients with parafoveal neovascular membranes, 
respectively. CNV had increased in size during the last 
follow-up visit in almost two thirds of the patients (62%). 
Based on these results, the authors drew the conclusion 
that PDT can be used for decelerating the natural course 
of macular CNV in angioid streaks because there are no 
other efﬁ  cient therapeutic modalities and also because the 
side effects of PDT are rare. The number of patients in this 
study is relatively sufﬁ  cient to draw safe conclusions, but the 
study was a retrospective one and the follow-up was very 
short (ﬁ  ve months).
Browning and colleagues55 designed a prospective study 
of 22 patients with angioid streaks who underwent PDT and 
were followed up for a short period of time (12 months). 
In this study, the PDT for patients with parafoveal CNV 
decelerated the course of the disorder. Similar results were 
presented by Heimann and colleagues56 in a retrospective 
study of 12 patients with a follow up of 12–50 months. 
According to their results, PDT seems to delay, but not 
prevent, the development of CNV in patients having angioid 
streaks and therefore these results suggest that modiﬁ  cations 
or combination of PDT with other treatment strategies can 
provide better results in the future.
Arias and colleagues57 reported on PDT in angioid streaks 
relatively recently. Ten patients (10 eyes) with pseudoxan-
thoma elasticum had PDT with an average 18-month follow 
up. The results were appalling since only three patients 
retained the initial visual acuity, while four patients had 
dramatic deterioration of visual function (more than six lines 
on the Snellen chart). Based on their ﬁ  nding, they concluded 
Figure 8 Fluorescein angiography of right eye with angioid streaks complicated by 
choroidal neovascularization.Therapeutics and Clinical Risk Management 2009:5 87
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that PDT is not effective in the treatment of macular CNV 
with the background of angioid streaks.
Ladas and colleagues58 evaluated the effectiveness of 
conventional PDT in a series of 24 eyes of 22 patients 
with CNV due to angioid streaks and compared it to the 
effectiveness of a PDT modiﬁ  cation where retreatments were 
performed earlier (every eight weeks instead of 12).
At the end of the follow-up, ﬁ  nal best-corrected visual 
acuity decreased in 21 of the total 24 eyes and In 19 eyes 
ﬁ  nal best-corrected visual acuity was equal to or less than 
20/400. There were not any statistically signiﬁ  cant differ-
ences in ﬁ  nal visual acuity between the two groups and 
the authors concluded that the functional and the anatomic 
results of PDT were not satisfactory, even when retreatments 
were performed earlier than the conventional time of three 
months.
In conclusion, from all previous studies and case reports 
it is evident that, despite the initial encouraging results from 
the application of PDT for the treatment of CNV in the 
macula, the end results did not fulﬁ  ll the initial expectations. 
In addition, several studies present contradictory results and 
others consider PDT as an adjuvant therapy that does not 
prevent, but slows down the natural course of CNV.
Antivascular endothelial growth 
factor treatment
Anti-vascular endothelial growth factor (VEGF) treatment 
has resulted in unprecedented visual and anatomic outcomes 
far outpacing other available treatments for CNV due to 
AMD.59–61 Today physicians and patients can expect visual 
stabilization in most patients and visual improvement in 
many, particularly if treatment is begun early in the course 
of the disease. PDT in combination with anti-VEGF has been 
also used for the treatment of CNV.62,63
Ranibizumab64 (Lucentis) is a recombinant humanized 
immunoglobulin G1 and isotype monoclonal antibody frag-
ment designed for intraocular use which binds to and inhibits 
the biologic activity of human VEGF A.
Bevacizumab,65 is a recombinant humanized full-length 
antibody that binds to all isoforms of VEGF, similar 
to ranibizumab which has been offered as an off-label 
intravitreal application for the treatment of wet AMD.
Wecke and colleagues66 reported favorable result in a 
patient with CNV due to angioid streaks after intravitreal 
injection of bevacizumab.
Chang and colleageus67 reported their results of 
intravitreous injection of bevacizumab for CNV from 
other causes than AMD and among them 11 patients 
suffered from angioid streaks. The CNV responded well 
to bevacizumab injections, however, as the authors stated, 
in between these eyes there was a high proportion of eyes 
that had previously undergone PDT so the results may 
have been biased.
Recently Donati and colleagues68 reported the use of 
intravitreal injection of bevacizumab for CNV in six eyes 
of ﬁ  ve patients with angioid streaks. The authors concluded 
that bevacizumab may be useful in the treatment of CNV 
due to angioid streaks. However, their results may have 
been compromised by the fact that all eyes had previously 
undergone PDT or laser photocoagulation.
Schiano-Lomoriello and colleagues69 reported two 
patients with CNV secondary to angioid streaks who received 
three intravitreal injections of bevacizumab and followed 
them for one year. The authors concluded that intravitreal 
injections of bevacizumab appeared to be an effective and 
safe treatment for CNV and resulted in a long-term CNV 
inactivation.
The results from 11 and six patients suffering from CNV 
associated with angioid streaks were reported recently by 
Neri and colleagues70 and Wiegand and colleagues,71 respec-
tively. In both studies, intravitreal bevacizumab was found 
to mildly reduce central foveal thickness and stabilize visual 
acuity. Both studies concluded that intravitreal bevacizumab 
may be a promising treatment. Future studies are required to 
validate their ﬁ  ndings.
In conclusion, the visual prognosis in patients with CNV 
secondary to angioid streaks, if untreated, is poor and most 
treatment modalities until recently have failed to limit the 
devastating impact of CNV in central vision.
However, it is likely that treatment with anti-VEGF, 
especially in treatment-naive eyes would yield favorable 
results and this has to be investigated by future studies.
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